In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IVTreatmentActive18 to 75Other20110101
NCT01307878

Trial Description

Summary

Evaluation of new adjuvant chemotherapy for unresectable liver metastasis of colorectal cancer without bleeding, obstruction, etc.

Eligibility Criteria

Inclusion Criteria:

  • age between 18 - 75 years old
  • colorectal adenocarcinoma pathologically
  • without any chemotherapy or radiotherapy
  • unresectable liver metastasis and without other metastasis
  • resectable colorectal cancer
  • suitable for chemotherapy
  • agreed by patients

Exclusion Criteria:

  • age below 18 years old or greater than 75 years old
  • haven't pathological diagnosis of colorectal adenocarcinoma
  • with any chemotherapy or radiotherapy
  • resectable liver metastasis or without other metastasis
  • unresectable colorectal cancer
  • unsuitable for chemotherapy
  • not agreed by patients

Trial Contact Information

Trial Lead Organizations/Sponsors

Medical Center of Fudan University

2nd Affiliated Hospital of Zhejiang University

2nd Affiliated Hospital of Zhejiang University

Jiangsu Provincial People's Hospital

Shanghai No. 6 Hospital

Shanghai No. 9 Hospital

Rui Jin Hospital

jianmin xu, doctorPh: 008613501984869
  Email: xujmin@yahoo.com.cn

Trial Sites

China
  Shanghai
 Medical Center of Fudan University
 jianmin xu, doctor Ph: 008613501984869
  Email: xujmin@yahoo.com.cn

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01307878
Information obtained from ClinicalTrials.gov on April 21, 2013

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top